Rimeporide in Patients With Duchenne Muscular Dystrophy

PHASE1CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

March 31, 2016

Primary Completion Date

December 31, 2017

Study Completion Date

February 28, 2018

Conditions
Muscular Dystrophy, Duchenne
Interventions
DRUG

Rimeporide

"Cohort 1:~50 mg TID in patients with a body weight ≤ 30kg at Baseline and 75 mg TID in patients with a body weight \> 30kg at Baseline~Cohort 2:~100mg TID in patients with a body weight ≤ 30kg at baseline and 150 mg TID in patients with a body weight \> 30kg at Baseline~Cohort 3:~150 mg TID in patients with a body weight ≤ 30kg at baseline and 200 mg TID in patients with a body weight \> 30kg at Baseline~Cohort 4:~200 mg TID in patients with a body weight ≤ 30kg at Baseline and 300 mg TID mg TID in patients with a body weight \> 30kg at Baseline"

Trial Locations (4)

20132

San Raffaele Hospital, Milan

75012

I-Motion - Hôpital Armand Trousseau, Paris

08041

Santa Creu i Sant Pau Hospital, Barcelona

WC1N 1EH

UCL Institute of Child Health and Great Ormond Street Hospital, London

All Listed Sponsors
lead

EspeRare Foundation

OTHER

NCT02710591 - Rimeporide in Patients With Duchenne Muscular Dystrophy | Biotech Hunter | Biotech Hunter